Krajina: Spojené štáty
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
ceftizoxime sodium (UNII: 26337D5X88) (ceftizoxime - UNII:C43C467DPE)
Fujisawa Healthcare, Inc.
ceftizoxime
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
1 g
INTRAVENOUS
PRESCRIPTION DRUG
Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflamma
Cefizox® (ceftizoxime for injection, USP) in ADD-Vantage® Vials equivalent to 1 gram ceftizoxime, packaged in tens equivalent to 2 grams ceftizoxime, packaged in tens Unreconstituted Cefizox should be protected from excessive light, and stored at controlled room temperature 15°-30°C (59°-86°F) in the original package until used. ADD-Vantage® is registered trademark of Abbott Laboratories. U.S. Patent 4,427,674 Product of Japan REFERENCES Manufactured for Fujisawa Healthcare, Inc. Deerfield, IL 60015-2548 by GlaxoSmithKline, Philadelphia, PA 19101
CEFIZOX- CEFTIZOXIME INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION FUJISAWA HEALTHCARE, INC. ---------- CEFIZOX® (CEFTIZOXIME FOR INJECTION, USP) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. FOR INTRAVENOUS INFUSION DES CRIPTION Cefizox (ceftizoxime for injection, USP) is a sterile, semisynthetic, broad spectrum, beta lactamase resistant cephalosporin antibiotic for parenteral (IV, IM) administration. It is the sodium salt of [6R- [6a,7β(Z)]] 7 [[(2,3 dihydro 2 imino 4 thiazolyl) (methoxyimino) acetyl] amino] 8 oxo 5 thia 1 azabicyclo [4.2.0] oct 2 ene 2 carboxylic acid. Its sodium content is approximately 60 mg (2.6 mEq) per gram of ceftizoxime activity. It has the following structural formula: C H N NAO S 405.38 Ceftizoxime for injection, USP is a white to pale yellow crystalline powder. Cefizox is supplied in ADD-vantage vials as ceftizoxime sodium equivalent to 1 gram or 2 grams ceftizoxime. CLINICAL PHARMACOLOGY Following IV administration of 1, 2, and 3 gram doses of Cefizox to normal volunteers, the following serum levels were obtained. SERUM CONCENTRATIONS AFTER INTRAVENOUS ADMINISTRATION Serum Concentration (µg/mL) Dose 5 min 10 min 30 min 1 hr 2 hr 4 hr 8 hr 1 gram 60.5 38.9 21.5 8.4 1.4 2 grams 131.8 110.9 77.5 53.6 33.1 12.1 2.0 ® 13 12 5 5 2 ® * * * 3 grams 221.1 174.0 112.7 83.9 47.4 26.2 4.8 A serum half life of approximately 1.7 hours was observed after IV or IM administration. Cefizox is 30% protein bound. Cefizox is not metabolized, and is excreted virtually unchanged by the kidneys in 24 hours. This provides a high urinary concentration. Concentrations greater than 6000 μg/mL have been achieved in the urine by 2 hours after a 1 gram dose of Cefizox intravenously. Probenecid slows tubular secretion and produces even higher serum levels, increasing the duration of measurable serum concentrat Prečítajte si celý dokument